CADLライブシグナル | Getagraph.comで利益を最大化

Live Chart Being Loaded With Signals

Commentary (30 4月 2024 @ 01:42):

Stats
本日の出来高	195 709
平均出来高	5.38M
時価総額	184.89M
EPS	$-0.290 ( 2023-11-09 )
次の収益日	( $0 ) 2024-05-09
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-4.81
ATR14	$0.0330 (0.52%)

Insider Trading

Date	Person	Action	Amount	type
2024-01-12	Schoch Charles	Sell	0	Common Stock
2024-01-12	Schoch Charles	Sell	0	Common Stock
2024-01-12	Schoch Charles	Sell	25 000	Stock Option (Right to Buy)
2024-01-12	Schoch Charles	Sell	39 498	Stock Option (Right to Buy)
2023-11-28	Tyagarajan Seshu	Sell	17 328	Common Stock

INSIDER POWER
76.67
Last 92 transactions
Buy: 8 106 969 \| Sell: 4 393 086

ボリューム相関

長: -0.26 (neutral)

短: 0.62 (weak)

Signal:(57.926) Neutral

Candel Therapeutics, Inc. 相関

10 最も正の相関
SRTS	0.913
CNDT	0.905
SYBX	0.89
CPIX	0.89
PSTV	0.879
FOSL	0.877
ATHE	0.87
EWTX	0.863
IMAB	0.861
LPCN	0.86

10 最も負の相関
TYHT	-0.863
AMRB	-0.848
IMRA	-0.845
RDUS	-0.838
XOG	-0.827
RDI	-0.825
VERX	-0.825
SGEN	-0.824
MPRA	-0.822
ZGNX	-0.821

知っていましたか？

相関は、2つの変数間の関係を説明する統計的指標です。相関係数は-1から1までの値を取り、-1は完全な負の相関（1つの変数が増加すると、もう一方は減少する）、1は完全な正の相関（1つの変数が増加すると、もう一方も増加する）、0は相関がないことを示します（変数間に関係がない）。

相関は、株式だけでなく、どの2つの変数間の関係にも適用できます。これは、金融、経済学、心理学などの分野で一般的に使用されています。

Candel Therapeutics, Inc. 相関 - 通貨/商品

0.50
( neutral )

0.40
( neutral )

0.00
( neutral )

-0.19
( neutral )

-0.51
( weak negative )

0.45
( neutral )

Candel Therapeutics, Inc. 財務諸表

Annual	2023
収益:	$0
総利益:	$-1.20M (0.00 %)
EPS:	$-1.310

FY	2023
収益:	$0
総利益:	$-1.20M (0.00 %)
EPS:	$-1.310

FY	2022
収益:	$125 000
総利益:	$-862 000 (-689.60 %)
EPS:	$-0.0994

FY	2021
収益:	$0.00
総利益:	$0.00 (0.00 %)
EPS:	$-1.934

Financial Reports:

No articles found.

Candel Therapeutics, Inc.

Candel Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the development immunotherapies for the cancer patients. The company develops CAN-2409, which is in Phase II clinical trails for the treatment of pancreatic cancer; Phase III clinical trials for the treatment of prostate cancer; and Phase II clinical trials for the treatment of lung cancer, as well as has completed Phase Ib/II clinical trials for the treatment of high-grade glioma. It also develops CAN-3110, which is in Phase I clinical trials for the treatment of recurrent glioblastoma. The company was formerly known as Advantagene, Inc. and changed its name to Candel Therapeutics, Inc. in November 2020. The company was incorporated in 2003 and is based in Needham, Massachusetts.